Bruker (BRKR)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$57.59+0.49%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Bruker’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+0.5%

+10% or more+5%0%−5%−10% or less

2.40 → 2.41 EPS · FY ending Dec 31, 2027 · 6 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 7 to 6; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	1.03B
EPS	—	0.903
FY 2026 · Annual
Revenue	$3.54B–$3.57B	3.56B
EPS	$2.1–$2.15non-GAAP	2.122
Organic revenue growth	1%–2%	—
FY 2027 · Annual
Revenue	—	3.7B
EPS	—	2.408

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve FY2026 non-GAAP EPS of $2.10 to $2.15	A primary condition in Bruker's published investment case. The stated target is >= $2.10.	Broken	EPS falls below $1.85	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. FY26 non-GAAP EPS guidance is $2.10 to $2.15, up 15% to 17% from $1.83 in FY25. Q2-26 non-GAAP EPS was $0.49, up from $0.32 in Q2-25, showing progress toward full-year targets. The trajectory is delivering EPS growth consistent with guidance. Delivery assessment Oct 24, 2026
Sustain growth via new product launches and semiconductor orders	New product launches and semiconductor orders support growth.	Improving	No growth or decline in semiconductor and overseas orders	Bookings accelerating vs maintain/increase target Q2 2026 results show accelerated bookings and maintained FY2026 revenue guidance of $3.54-$3.57B, reinforcing the growth driver. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain operating margin near 25% to 30% in FY2026	Profit margins are expected near 25% to 30%.	Broken	operating margin falls below 20%	Operating margin: -7.79% FY2026-Q2; GAAP. Published target: >=25%. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026-7.787716 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 7bb40a00-0f05-4af6-a682-29501d14b86a. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. FY26 revenue guidance remains at $3.54 to $3.57 billion, representing 3% to 4% reported growth over FY25's $3.44 billion. Organic growth is targeted at 1% to 2%. Actual revenue grew from $797.4 million in 2025-Q2 to $838.5 million in 2026-Q2 (+5.2% yoy). The trajectory is delivering consistent revenue growth aligned with guidance. Delivery assessment Oct 24, 2026
Achieve FY2026 revenue of $3.57 to $3.60 billion	A primary condition in Bruker's published investment case. The stated target is ~$3.585 billion.	Broken	annual revenue falls below $3.41 billion	Revenue: $838.5M FY2026-Q2; GAAP. Published target: ~$3.585 billion. Target period is not explicitly aligned with this observation. Source published Aug 5, 2026838,500,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 7bb40a00-0f05-4af6-a682-29501d14b86a. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. FY26 revenue guidance remains at $3.54 to $3.57 billion, representing 3% to 4% reported growth over FY25's $3.44 billion. Organic growth is targeted at 1% to 2%. Actual revenue grew from $797.4 million in 2025-Q2 to $838.5 million in 2026-Q2 (+5.2% yoy). The trajectory is delivering consistent revenue growth aligned with guidance. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$2.41

$2.43 → $2.41 · observed estimates

FY2027 revenue$3.70B

$3.74B → $3.70B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$2.43	$3,741,988,410	13 / 12
2026-07-25	$2.43	$3,741,988,410	13 / 12
2026-07-26	$2.43	$3,741,988,410	13 / 12
2026-07-27	$2.43	$3,741,988,410	13 / 12
2026-07-28	$2.43	$3,741,988,410	13 / 12
2026-07-29	$2.43	$3,741,988,410	13 / 12
2026-07-30	$2.43	$3,741,988,410	13 / 12
2026-07-31	$2.43	$3,741,988,410	13 / 12
2026-08-01	$2.43	$3,741,988,410	13 / 12
2026-08-02	$2.43	$3,741,988,410	13 / 12
2026-08-03	$2.43	$3,741,988,410	13 / 12
2026-08-04	$2.43	$3,741,988,410	13 / 12
2026-08-05	$2.43	$3,741,988,410	13 / 12
2026-08-06	$2.43	$3,741,988,410	13 / 12
2026-08-07	$2.41	$3,701,726,653	6 / 8
2026-08-08	$2.41	$3,701,726,653	6 / 8
2026-08-09	$2.40	$3,705,103,650	13 / 12
2026-08-10	$2.40	$3,705,103,650	13 / 12
2026-08-11	$2.41	$3,701,686,990	13 / 12
2026-08-12	$2.41	$3,701,686,990	13 / 12
2026-08-13	$2.41	$3,701,726,653	6 / 8
2026-08-14	$2.41	$3,701,726,653	6 / 8
2026-08-15	$2.41	$3,701,726,653	6 / 8
2026-08-16	$2.41	$3,701,726,653	6 / 8
2026-08-17	$2.41	$3,701,726,653	6 / 8
2026-08-18	$2.41	$3,701,726,653	6 / 8
2026-08-19	$2.41	$3,701,726,653	6 / 8
2026-08-20	$2.41	$3,701,726,653	6 / 8
2026-08-21	$2.41	$3,701,726,653	6 / 8
2026-08-22	$2.41	$3,701,726,653	6 / 8
2026-08-23	$2.41	$3,701,726,653	6 / 8
2026-08-24	$2.41	$3,701,726,653	6 / 8
2026-08-25	$2.41	$3,701,726,653	6 / 8
2026-08-26	$2.41	$3,701,726,653	6 / 8
2026-08-27	$2.41	$3,701,726,653	6 / 8
2026-08-28	$2.41	$3,701,726,653	6 / 8
2026-08-29	$2.41	$3,701,726,653	6 / 8
2026-08-30	$2.41	$3,701,726,653	6 / 8
2026-08-31	$2.41	$3,701,726,653	6 / 8
2026-09-01	$2.41	$3,701,726,653	6 / 8
2026-09-02	$2.41	$3,701,726,653	6 / 8
2026-09-03	$2.41	$3,701,726,653	6 / 8
2026-09-04	$2.41	$3,701,726,653	6 / 8
2026-09-05	$2.41	$3,701,726,653	6 / 8
2026-09-06	$2.41	$3,701,726,653	6 / 8
2026-09-07	$2.41	$3,701,726,653	6 / 8
2026-09-08	$2.41	$3,701,726,653	6 / 8
2026-09-09	$2.41	$3,701,726,653	6 / 8
2026-09-10	$2.40	$3,701,221,203	6 / 9
2026-09-11	$2.40	$3,701,221,203	6 / 9
2026-09-12	$2.40	$3,701,221,203	7 / 9
2026-09-13	$2.40	$3,701,221,203	7 / 9
2026-09-14	$2.40	$3,701,221,203	7 / 9
2026-09-15	$2.40	$3,701,221,203	7 / 9
2026-09-16	$2.40	$3,701,221,203	7 / 9
2026-09-17	$2.40	$3,701,221,203	7 / 9
2026-09-18	$2.40	$3,701,221,203	7 / 9
2026-09-19	$2.40	$3,701,221,203	7 / 9
2026-09-20	$2.40	$3,701,221,203	7 / 9
2026-09-21	$2.40	$3,702,261,895	7 / 9
2026-09-22	$2.40	$3,702,261,895	7 / 9
2026-09-23	$2.40	$3,702,261,895	7 / 9
2026-09-24	$2.40	$3,702,261,895	7 / 9
2026-09-25	$2.40	$3,702,261,895	7 / 9
2026-09-26	$2.40	$3,702,261,895	7 / 9
2026-09-27	$2.40	$3,702,261,895	7 / 9
2026-09-28	$2.40	$3,702,261,895	7 / 9
2026-09-29	$2.40	$3,702,261,895	7 / 9
2026-09-30	$2.40	$3,702,261,895	7 / 9
2026-10-01	$2.40	$3,702,261,895	6 / 8
2026-10-02	$2.40	$3,704,508,720	6 / 8
2026-10-03	$2.40	$3,704,508,720	6 / 8
2026-10-04	$2.40	$3,704,508,720	6 / 8
2026-10-05	$2.40	$3,704,508,720	6 / 8
2026-10-06	$2.40	$3,704,508,720	6 / 8
2026-10-07	$2.40	$3,704,508,720	6 / 8
2026-10-08	$2.42	$3,704,368,744	6 / 8
2026-10-09	$2.42	$3,704,368,744	6 / 8
2026-10-10	$2.42	$3,704,368,744	6 / 8
2026-10-11	$2.42	$3,704,368,046	6 / 8
2026-10-12	$2.42	$3,704,368,046	6 / 8
2026-10-13	$2.42	$3,704,368,046	6 / 8
2026-10-14	$2.42	$3,704,393,046	6 / 8
2026-10-15	$2.42	$3,704,393,046	6 / 8
2026-10-16	$2.41	$3,704,120,189	6 / 8
2026-10-17	$2.41	$3,704,120,189	6 / 8
2026-10-18	$2.41	$3,704,120,189	6 / 8
2026-10-19	$2.41	$3,704,120,189	6 / 8
2026-10-20	$2.41	$3,704,120,189	6 / 8
2026-10-21	$2.41	$3,704,120,189	6 / 8
2026-10-22	$2.41	$3,704,120,189	6 / 8
2026-10-23	$2.41	$3,704,120,189	6 / 8
2026-10-24	$2.41	$3,704,120,189	6 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	9	4	1
2026-06-01	9	4	1
2026-07-01	8	4	1
2026-08-01	8	4	1
2026-09-01	8	5	1
2026-10-01	7	6	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 6 Hold · 1 Sell / Strong Sell

0 upgrades1 downgrades4 maintains

Recent actions · Sep 25–Oct 24 · 5 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

BarclaysOct 7 · prior May 7

$53.00 → $70.00+32.1%

Leerink PartnersSep 29

$80.00New observation · no comparable prior

$0$44.00$88.00

1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve FY2026 non-GAAP EPS of $2.10 to $2.15Published status: Broken
Maintain operating margin near 25% to 30% in FY2026Published status: Broken
Achieve FY2026 revenue of $3.57 to $3.60 billionPublished status: Broken

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-39.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Bruker outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a medical-technology business with a currently improving earnings and margin profile. The long-term thesis is intact, with recent financial performance in the top half of its industry, but the risk level is elevated.

What's priced into Bruker

Valuation is broadly aligned with the model’s expectations, and the priced-in signal is marked justified with low fragility. BRKR trades at about a 3% premium to peers, so the evidence points to a near-peer valuation rather than a large expectations gap.

What the fundamentals likely do

Near term, management is on track with FY2026 revenue and non-GAAP earnings guidance, while recent results show revenue growth and wider operating margins. The main near-term risk is a guidance cut; the stated miss risk is low, though a deep miss in recent history and peer misses warrant attention.

What Bruker hinges on

Over the next few quarters, the thesis depends on maintaining guidance and continuing margin improvement. Weaker job growth could raise recession concerns for cyclical healthcare names, while continued strong results from sector peers could support the sector backdrop.